Neurophth Biotechnology picks up $61.9m Series B

Neurophth Biotechnology Ltd., a genetic medicines company, has raised $61.9 million in Series B financing.

9 February 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles